Transplantation of Bone Marrow-derived Mononuclear Cells in Ischemic Apolipoprotein E-knockout Mice Accelerates Atherosclerosis Without Altering Plaque Composition
Overview
Authors
Affiliations
Background: Bone marrow-derived mononuclear cells (BM-MNCs) enhance postischemic neovascularization, and their therapeutic use is currently under clinical investigation. We evaluated the safety of BM-MNC-based therapy in the setting of atherosclerosis.
Methods And Results: Apolipoprotein E (apoE)-knockout (KO) mice were divided into 4 groups: 20 nonischemic mice receiving intravenous injection of either saline (n=10) or 10(6) BM-MNCs from wild-type animals (n=10) and 20 mice with arterial femoral ligature receiving intravenous injection of either saline (n=10) or 10(6) BM-MNCs from wild-type animals (n=10) at the time of ischemia induction. Animals were monitored for 4 additional weeks. Atherosclerosis was evaluated in the aortic sinus. BM-MNC transplantation improved tissue neovascularization in ischemic hind limbs, as revealed by the 210% increase in angiography score (P<0.0001), the 33% increase in capillary density (P=0.01), and the 65% increase in tissue Doppler perfusion score (P=0.0002). Hindlimb ischemia without BM-MNC transplantation or BM-MNC transplantation without ischemia did not affect atherosclerotic plaque size. However, transplantation of 10(6) BM-MNCs into apoE-KO mice with hindlimb ischemia induced a significant 48% to 72% increase in lesion size compared with the other 3 groups (P=0.0025), despite similar total cholesterol levels. Transplantation of 10(5) BM-MNCs produced similar results, whereas transplantation of 10(6) apoE-KO-derived BM-MNCs had neither proangiogenic nor proatherogenic effects. There was no difference in plaque composition between groups.
Conclusions: BM-MNC therapy is unlikely to affect atherosclerotic plaque stability in the short term. However, it may promote further atherosclerotic plaque progression in an ischemic setting.
van Rhijn-Brouwer F, Wever K, Kiffen R, van Rhijn J, Gremmels H, Fledderus J Dis Model Mech. 2024; 17(5).
PMID: 38616715 PMC: 11139036. DOI: 10.1242/dmm.050632.
Dabrowski W, Tekieli L, Mazurek A, Lanocha M, Banys R, Zmudka K Postepy Kardiol Interwencyjnej. 2023; 18(4):483-495.
PMID: 36967840 PMC: 10031661. DOI: 10.5114/aic.2023.125609.
Coppin E, Zhang X, Ohayon L, Johny E, Dasari A, Zheng K Arterioscler Thromb Vasc Biol. 2023; 43(6):889-906.
PMID: 36891902 PMC: 10213134. DOI: 10.1161/ATVBAHA.123.318956.
Endothelial Progenitor Cells in Coronary Artery Disease: From Bench to Bedside.
Pelliccia F, Zimarino M, De Luca G, Viceconte N, Tanzilli G, De Caterina R Stem Cells Transl Med. 2022; 11(5):451-460.
PMID: 35365823 PMC: 9154346. DOI: 10.1093/stcltm/szac010.
Wang M, Yang D, Hu Z, Shi Y, Ma Y, Cao X Front Cardiovasc Med. 2021; 8:747497.
PMID: 34708093 PMC: 8542843. DOI: 10.3389/fcvm.2021.747497.